Related references
Note: Only part of the references are listed.CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor
Jia-Shiong Chen et al.
SCIENTIFIC REPORTS (2022)
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)
The Multiple Potential Biomarkers for Predicting Immunotherapy Response-Finding the Needle in the Haystack
Tamiem Adam et al.
CANCERS (2021)
Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics
Julianne D. Twomey et al.
AAPS JOURNAL (2021)
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Karthik Dhatchinamoorthy et al.
FRONTIERS IN IMMUNOLOGY (2021)
Targeting the Tumor Microenvironment for Improving Therapeutic Effectiveness in Cancer Immunotherapy: Focusing on Immune Checkpoint Inhibitors and Combination Therapies
I-Tsu Chyuan et al.
CANCERS (2021)
Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth
Dennis Doleschel et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
Sonja Vukadin et al.
BIOMEDICINES (2021)
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer
Yong Jun Lee et al.
MOLECULES AND CELLS (2021)
Comparison of the molecular and cellular phenotypes of common mouse syngeneic models with human tumors
Wenyan Zhong et al.
BMC GENOMICS (2020)
Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma
Ann-Lii Cheng et al.
JOURNAL OF HEPATOLOGY (2020)
Anti-angiogenesis therapy overcomes the innate resistance to PD-1/PD-L1 blockade in VEGFA-overexpressed mouse tumor models
Qiaohong Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
The biomarkers of hyperprogressive disease in PD-1/PD-L1 blockage therapy
Xueping Wang et al.
MOLECULAR CANCER (2020)
Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma
Gabriel Schwartz et al.
TARGETED ONCOLOGY (2020)
A decade of immune-checkpoint inhibitors in cancer therapy
Caroline Robert
NATURE COMMUNICATIONS (2020)
Diagnosis and Management of Hematological Adverse Events Induced by Immune Checkpoint Inhibitors: A Systematic Review
Nabil E. Omar et al.
FRONTIERS IN IMMUNOLOGY (2020)
Roles of IFN-γ in tumor progression and regression: a review
Dragica Jorgovanovic et al.
BIOMARKER RESEARCH (2020)
Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma
Kohei Shigeta et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy (vol 120, pg 346, 2019)
Can Liu et al.
BRITISH JOURNAL OF CANCER (2019)
PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
Takahiro Kamada et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang et al.
LANCET ONCOLOGY (2019)
CAR-T the living drugs, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Delong Liu
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction
Shixiang Wang et al.
ELIFE (2019)
Third- or Later-line Therapy for Metastatic Colorectal Cancer: Reviewing Best Practice
Tanios Bekaii-Saab et al.
CLINICAL COLORECTAL CANCER (2019)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer
Lydia Meder et al.
CANCER RESEARCH (2018)
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
Caroline Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeting immune checkpoints potentiates immunoediting and changes the dynamics of tumor evolution
Mirjana Efremova et al.
NATURE COMMUNICATIONS (2018)
Targeting veGF/veGFR to Modulate Antitumor immunity
Ju Yang et al.
FRONTIERS IN IMMUNOLOGY (2018)
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8(+) T cells in the tumor microenvironment
Yasuko Tada et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Keehoon Jung et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
TAM receptor tyrosine kinase function and the immunopathology of liver disease
S. K. Mukherjee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2016)
Inhibition of HIF-1α enhances anti-tumor effects of dendritic cell-based vaccination in a mouse model of breast cancer
Nasim Kheshtchin et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
Dieter Zopf et al.
CANCER MEDICINE (2016)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
Li Liu et al.
CLINICAL CANCER RESEARCH (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
Xian-De Liu et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
Brian Ruffell et al.
CANCER CELL (2014)
PD-L1 is a novel direct target of HIF-1α., and its blockade under hypoxia enhanced MDSC-mediated T cell activation
Muhammad Zaeem Noman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
Magali Terme et al.
CANCER RESEARCH (2013)
Deciphering and Reversing Tumor Immune Suppression
Greg T. Motz et al.
IMMUNITY (2013)
Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function
Madhusudhanan Sukumar et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
The Key Role of IL-6-Arginase Cascade for Inducing Dendritic Cell-Dependent CD4+ T Cell Dysfunction in Tumor-Bearing Mice
Yoshinori Narita et al.
JOURNAL OF IMMUNOLOGY (2013)
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Wiebke Hansen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics
Amanda W. Lund et al.
CELL REPORTS (2012)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Expression of hypoxia-inducible factor-1α, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma
Kotaro Miyake et al.
PANCREAS (2008)
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1α
David Z. Qian et al.
CANCER RESEARCH (2006)
Share Paper
